Influence of Prostate Volume on Targeted Biopsy Outcomes and PI-RADS Predictive Value for Significant Prostate Cancer

<b>Background/Objectives</b>: Multiparametric MRI (mpMRI) and targeted biopsies have revolutionized prostate cancer (PC) detection through the Prostate Imaging Reporting and Data System (PIRADS). However, the effect of prostate volume on cancer detection and the predictive accuracy of PIRADS in the mpMRI-guided biopsy era remains unclear. The aim was to assess whether prostate volume affects detection rates of clinically significant prostate cancer (CSPC) and high-risk prostate cancer (HRPC) and modifies the predictive performance of the PIRADS score. <b>Methods</b>: We retrospectively analyzed 361 biopsy-naïve men who underwent mpMRI-fusion transperineal biopsies between 2016 and 2023. Lesions graded PIRADS ≥ 3 were targeted alongside systematic sampling. A receiver-operating characteristic (ROC) curve (AUC = 0.74) defined a 44 mL cutoff separating small (<44 mL; n = 160) and large (≥44 mL; n = 193) prostates. Logistic regression and cubic-spline analyses evaluated associations between prostate volume, PIRADS, and cancer outcomes. <b>Results</b>: Any cancer was detected in 74.3% of small versus 35.5% of large prostates (<i>p</i> < 0.001); CSPC in 42.5% vs. 19.6% (<i>p</i> < 0.001); HRPC in 14.3% vs. 5.5% (<i>p</i> < 0.001). Small prostate volume independently predicted any cancer (OR 7.31; 95% CI 4.22-12.7), CSPC (OR 5.08; 95% CI 2.87-8.99), and HRPC (OR 4.50; 95% CI 1.80-11.3). Between 40 and 70 mL, each 10 mL increase in volume reduced CSPC risk by 61% (<i>p</i> = 0.008). Prostate volume significantly modified PIRADS accuracy: in large glands, PIRADS 3 lesions carried only 2% risk for CSPC and 0% for HRPC, while in small prostates, PIRADS 3 conferred a 16.9-fold increased CSPC risk. <b>Conclusions</b>: Prostate volume inversely correlates with cancer detection and aggressiveness. PIRADS performance is volume-dependent; PIRADS 3 lesions in large prostates rarely represent significant cancer and may not warrant biopsy.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2025-11-29
DOI
https://doi.org/10.3390/jcm14238476
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influence of Prostate Volume on Targeted Biopsy Outcomes and PI-RADS Predictive Value for Significant Prostate Cancer

Yuval Avda, Alícia Marsà, Daniel N. Lerman, Roy Croock et al.
Journal of Clinical Medicine
Prostate Cancer Diagnosis and Treatment
article

Influence of Prostate Volume on Targeted Biopsy Outcomes and PI-RADS Predictive Value for Significant Prostate Cancer

Yuval Avda, Alícia Marsà, Daniel N. Lerman, Roy Croock, Morad Jaber, Igal Shpunt, Dor Rubinshtein, Yaniv Shilo, Jonathan Modai, V. M. Smolyakov, Dan Leibovici, Ilia Beberashvili, Gal Goldshtein, Shir Tiger, Wael Shahabri
article en

Abstract

<b>Background/Objectives</b>: Multiparametric MRI (mpMRI) and targeted biopsies have revolutionized prostate cancer (PC) detection through the Prostate Imaging Reporting and Data System (PIRADS). However, the effect of prostate volume on cancer detection and the predictive accuracy of PIRADS in the mpMRI-guided biopsy era remains unclear. The aim was to assess whether prostate volume affects detection rates of clinically significant prostate cancer (CSPC) and high-risk prostate cancer (HRPC) and modifies the predictive performance of the PIRADS score. <b>Methods</b>: We retrospectively analyzed 361 biopsy-naïve men who underwent mpMRI-fusion transperineal biopsies between 2016 and 2023. Lesions graded PIRADS ≥ 3 were targeted alongside systematic sampling. A receiver-operating characteristic (ROC) curve (AUC = 0.74) defined a 44 mL cutoff separating small (<44 mL; n = 160) and large (≥44 mL; n = 193) prostates. Logistic regression and cubic-spline analyses evaluated associations between prostate volume, PIRADS, and cancer outcomes. <b>Results</b>: Any cancer was detected in 74.3% of small versus 35.5% of large prostates (<i>p</i> < 0.001); CSPC in 42.5% vs. 19.6% (<i>p</i> < 0.001); HRPC in 14.3% vs. 5.5% (<i>p</i> < 0.001). Small prostate volume independently predicted any cancer (OR 7.31; 95% CI 4.22-12.7), CSPC (OR 5.08; 95% CI 2.87-8.99), and HRPC (OR 4.50; 95% CI 1.80-11.3). Between 40 and 70 mL, each 10 mL increase in volume reduced CSPC risk by 61% (<i>p</i> = 0.008). Prostate volume significantly modified PIRADS accuracy: in large glands, PIRADS 3 lesions carried only 2% risk for CSPC and 0% for HRPC, while in small prostates, PIRADS 3 conferred a 16.9-fold increased CSPC risk. <b>Conclusions</b>: Prostate volume inversely correlates with cancer detection and aggressiveness. PIRADS performance is volume-dependent; PIRADS 3 lesions in large prostates rarely represent significant cancer and may not warrant biopsy.

Journal of Clinical MedicineVol. 14(23)
Kaplan Medical Center (IL), Rabin Medical Center (IL), Assuta Medical Center (IL), Laniado Hospital (IL), Assaf Harofeh Medical Center (IL)
Openalex Percentile: Top 43%
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.